Discontinuation of acetylcholinesterase inhibitor treatment in the nursing home

American Journal Geriatric Pharmacotherapy

Volumn 9, Issue 5, 2011, Pages 345-350

  Mansour, Daniel ^a   Wong, Remy ^b   Kuskowski, Michael ^c   Dysken, Maurice ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c VA MEDICAL CENTER   (United States)

Author keywords

acetylcholinesterase inhibitors; Alzheimer's disease; death; nursing home

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINESTERASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; GALANTAMINE; HYPNOTIC AGENT; NEUROLEPTIC AGENT; RIVASTIGMINE; TACRINE;

AGED; ALZHEIMER DISEASE; ARTICLE; DEATH; DRUG WITHDRAWAL; DYING; FEMALE; HOSPICE CARE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NURSING HOME PATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOMES FOR THE AGED; HOSPICES; HUMANS; LENGTH OF STAY; MALE; MEDICAL FUTILITY; MINNESOTA; NURSING HOMES; PATIENT ADMISSION; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TERMINAL CARE; TIME FACTORS; VETERANS;

EID: 80054090184     PISSN: 15435946     EISSN: 18767761     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2011.08.004     Document Type: Article

References (18)

1. K. Blennow, M.J. deLeon, and H. Zetterberg Alzheimer's disease The Lancet 368 2006 387 403 (Pubitemid 44108123)
2. Updated Criteria for Use: Cholinesterase Inhibitors to Treat Dementia: VHA Pharmacy Benefits Management Service and the Medical Advisory Panel http://www.pbm.va.gov July 2008 Accessed September 6, 2011
3. D.B. Hogan, P. Bailey, and S. Black Diagnosis and treatment of dementia: 5 Nonpharmacologic and pharmacologic therapy for mild to moderate dementia CMAJ 179 2008 1019 1026
4. P. Raina, P. Santaguida, and A. Ismaila Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Ann Int Med 148 2008 379 397 (Pubitemid 351665469)
5. R.S. Doody, J.C. Stevens, and R.N. Beck Practice parameter: management of dementia (an evidence-based review) Neurology 56 2001 1154 1166
6. P.V. Rabins, D. Blacker, and B.W. Rovner American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias, 2nd edition http://ajp.psychiatryonline.org/cgi/data/164/12/ A48/DC2/1 2007 Accessed September 6, 2011
7. L.A. Hershey, W. Korchik, and J.R. McCarten Veterans Health Administration: the pharmacologic management of cognitive changes in Alzheimer's disease http://vaww.national.cmop.va.gov/PBM/Clinical%20Guidance/ Archived%20Criteria,%20Guidelines%20and%20Reviews/ Treatment%20Guidelines%20(Archive)/ Cognitive%20Changes%20in%20Alzheimer%27s%20Disease%20(Pharmacologic%20Managemen t).pdf 1999 Accessed September 6, 2011
8. Centers for Medicare and Medicaid Services: Minimum Data Set MSD Public Quality Indicator and Resident Reports http://www.cms.gov/MDSPubQIandResRep Accessed September 6, 2011
9. H. Umegaki, A. Itoh, Y. Suzuki, and T. Nabeshima Discontinuation of donepezil for the treatment of Alzheimer's dementia in geriatric practice Int Psychogeriatr 20 2008 800 806 (Pubitemid 351704882)
10. M.A. Raskind, E.R. Peskind, and L. Truyen The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial Arch Neurol 61 2004 253 256
11. H. Feldman, S. Gauthier, J. Hecker Donepezil MSAD Study Investigators Group A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology 57 2001 613 620 (Pubitemid 32782987)
12. A. Homma, Y. Imai, and H. Tago Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial Dement Geriatr Cogn Disord 25 2008 399 407 (Pubitemid 351630073)
13. H. Feldman, S. Gauthier, J. Hecker Donepezil MSAD Study Investigators Group Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial Int J Geriatr Psychiatry 20 2005 559 569 (Pubitemid 40873349)
14. B. Winblad, L. Kilander, S. Eriksson Severe Alzheimer's disease Study Group Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study Lancet 367 2006 1057 1065
15. H. Feldman, S. Gauthier, J. Hecker The Donepezil MSAD Study Investigators Group Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden J Am Geriatr Soc 51 2003 737 744 (Pubitemid 36693421)
16. D.J. Weschules, T.L. Maxwell, and J.W. Shega Acetylcholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia J Palliat Med 11 2008 738 745 (Pubitemid 351918841)
17. J.W. Shega, L. Ellner, D.T. Lau, and T.L. Maxwell Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end stage dementia: a survey of hospice medical directors J Palliat Med 12 2009 779 783
18. National Consensus Project for Quality Palliative Care Clinical Practice Guidelines for Quality Palliative Care, Second Edition http://www. nationalconsensusproject.org/Guidelines-Download.asp 2009 Accessed September 6, 2011